Overview
Metastatic carcinoma involving the stomach represents a significant clinical challenge, often presenting with advanced disease characteristics and poor prognosis. Gastric cancer frequently metastasizes to sites such as the peritoneum, lymph nodes, and solid organs, complicating treatment strategies and impacting patient quality of life (QoL). Despite global efforts to reduce incidence and mortality rates, gastric cancer remains a leading cause of cancer-related deaths, particularly in developing nations. The management of metastatic gastric cancer focuses heavily on supportive care, addressing symptoms like anorexia and cachexia, while exploring potential benefits from targeted interventions such as surgical resection and systemic therapies. Understanding the pathophysiology, clinical presentation, and evolving treatment paradigms is crucial for optimizing patient outcomes.
Pathophysiology
The pathophysiology of metastatic carcinoma in the stomach is multifaceted, with cancer cachexia playing a pivotal role. Elevated plasma ghrelin levels, typically associated with appetite stimulation, do not prevent anorexia in patients with cancer cachexia, indicating a state of ghrelin resistance [PMID:28249026]. This resistance is thought to be a critical mechanism underlying the anorexia observed in advanced gastric cancer patients, contributing significantly to weight loss and muscle wasting. Cachexia, characterized by involuntary weight loss and skeletal muscle depletion, is directly responsible for up to one-fifth of cancer deaths and profoundly affects both patients and their caregivers, exacerbating psychological distress such as anxiety and depression [PMID:40320515]. The interplay between metabolic dysregulation, hormonal imbalances, and systemic inflammation further complicates the clinical picture, necessitating a holistic approach to management that addresses both physical and psychological aspects of the disease.
Epidemiology
Gastric cancer frequently presents with metastatic involvement at diagnosis, affecting approximately 40% of patients, with the peritoneum being a common site of dissemination, occurring synchronously in about 14% of cases [PMID:31060544]. Despite global trends showing declines in cancer incidence and mortality, gastric cancer remains a significant public health concern, particularly in developing countries where it contributes substantially to cancer mortality rates [PMID:21864355]. The epidemiology underscores the need for early detection and intervention strategies to mitigate the impact of metastatic spread. Regional variations in incidence highlight the importance of tailored public health initiatives and screening programs to address disparities in outcomes.
Clinical Presentation
Patients with metastatic carcinoma of the stomach often present with a constellation of symptoms that significantly impact their quality of life. Progressive weight loss and anorexia are hallmark features, frequently accompanied by psychological distress, including heightened anxiety and depression, not only in patients but also in their caregivers [PMID:40320515]. Early satiety, characterized by a feeling of fullness early in a meal, portends a poor prognosis, with a 30% increased risk of mortality [PMID:28249026]. The presence of involuntary weight loss and muscle wasting underscores the severity of cachexia, which is a major contributor to morbidity and mortality in these patients [PMID:27367202]. Metastatic sites commonly include the peritoneum (46%), non-regional lymph nodes (8%), solid organs (14%), and adjacent organs (3.3%), often in combination, complicating the clinical picture [PMID:35128998]. Functional status, as measured by Eastern Cooperative Oncology Group (ECOG) performance scores, significantly differentiates patients receiving supportive care from those who do not, indicating better outcomes with comprehensive supportive measures [PMID:25735358].
Diagnosis
Diagnosing metastatic carcinoma in the stomach involves a combination of imaging modalities and specific diagnostic criteria. Computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography-CT (PET-CT) are essential tools for identifying metastatic spread, with oligometastatic disease (OMD) defined by the presence of three or fewer metastatic sites [PMID:37729281]. Limited peritoneal dissemination, often assessed using the Peritoneal Cancer Index (PCI) score below 7, is crucial for surgical considerations [PMID:31060544]. Distinguishing metastatic tumors, particularly Krukenberg tumors (KTs), from primary ovarian cancer is critical and can be aided by immunohistochemical markers such as CK7(+), CK20(-), CDX2(+), and CA125(-), which suggest an upper gastrointestinal tract origin [PMID:29785081]. While tools like the Nutrition Risk Score (NRS) and Mini Nutritional Assessment (MNA) assess current nutritional status, they fall short in predicting impending weight loss, highlighting the need for more predictive biomarkers [PMID:27367202]. Tumor markers like TAP (tumor-associated peptide) show promise in monitoring treatment response, particularly in advanced gastric cancer, offering a more dynamic assessment compared to conventional markers like CEA, CA125, and CA19-9 [PMID:25987083].
Differential Diagnosis
Differentiating metastatic gastric carcinoma from other conditions can be challenging due to overlapping symptoms and imaging findings. Anorexia and weight loss, while hallmark symptoms of metastatic disease, are often perceived more severely by caregivers than by patients themselves, indicating potential discrepancies in symptom appraisal [PMID:40320515]. This discrepancy underscores the importance of comprehensive patient and caregiver communication in clinical assessments. Other gastrointestinal malignancies, inflammatory conditions, and even certain metabolic disorders can mimic the clinical presentation of metastatic gastric cancer, necessitating thorough diagnostic workups including biopsies and advanced imaging techniques to confirm the diagnosis accurately.
Management
The management of metastatic carcinoma in the stomach primarily revolves around supportive care, given the limited efficacy of curative treatments in advanced stages. Nutrition support is paramount, addressing the significant issues of anorexia and cachexia. Despite controversies, the use of artificial nutrition (ANH) remains prevalent, though evidence suggests it does not improve quality of life (QoL) or life expectancy in terminal cancer patients [PMID:40325835]. The persistence of ANH use may stem from perceived psychological benefits or to avoid feelings of abandonment by healthcare providers. Multidisciplinary supportive care, including psychological support and nutritional counseling, is essential for improving patient outcomes and QoL [PMID:40320515]. Emerging evidence supports the integration of surgical interventions, such as cytoreductive surgery (CRS) combined with intraperitoneal chemotherapy (IPC) and hyperthermic intraperitoneal chemotherapy (HIPEC), particularly in selected patients with peritoneal dissemination, showing potential survival benefits [PMID:31060544]. Palliative chemotherapy and targeted therapies, such as the use of Rikkunshito (RKT) to potentiate ghrelin signaling and alleviate cachexia symptoms, offer additional avenues for symptom management [PMID:28249026]. The SNAQ tool, which predicts significant weight loss within six months, can facilitate timely nutritional interventions, enhancing patient care [PMID:27367202]. However, variability in clinical practice and adherence to guidelines highlights the need for standardized protocols and further research to clarify optimal treatment strategies [PMID:21864355].
Complications
Metastatic gastric carcinoma and its management pose several complications that impact both patient health and QoL. Postoperative complications following palliative surgeries, such as gastrectomies and bypass procedures, occur in about 52% of cases, though mortality rates remain relatively low at around 2.1% [PMID:35128998]. Psychological morbidity often extends beyond the patient to caregivers, creating a bidirectional impact where distress in one affects the other, emphasizing the necessity for holistic support strategies [PMID:40320515]. Additionally, treatments like targeted locoregional therapy (TLT) can introduce higher incidences of toxicities compared to best supportive care (BSC), necessitating careful risk-benefit assessments [PMID:28693801]. Managing these complications requires a multidisciplinary approach, integrating medical, surgical, and psychological support to address the multifaceted needs of patients and their families.
Prognosis & Follow-up
The prognosis for patients with metastatic gastric carcinoma remains guarded, with significant weight loss and anorexia often predicting a median survival of less than four months [PMID:40320515]. Peritoneal dissemination carries an especially dismal prognosis, with median overall survival typically ranging from 3 to 4 months [PMID:31060544]. Despite advancements in supportive care and targeted therapies, the lack of robust quality of life (QoL) data in many studies underscores the need for more comprehensive assessments in future research [PMID:28693801]. Follow-up practices post-treatment vary widely among oncologists, with some advocating for re-staging using CT, MRI, or PET-CT scans to monitor disease progression and response to therapy [PMID:37729281]. Regular reassessment of ECOG performance status and nutritional markers like TAP can guide ongoing management decisions and ensure timely interventions to maintain patient comfort and functional status.
Special Populations
Special considerations are necessary for specific patient populations, including those receiving artificial nutrition (ANH) and those managed by multidisciplinary teams. Dietitians, despite their expertise in nutrition, are often underrepresented in decision-making processes regarding ANH for terminal cancer patients, highlighting a gap in recognizing their critical role in patient care [PMID:40325835]. Additionally, elderly patients and those with comorbidities may require tailored approaches to balance the benefits of aggressive interventions against potential risks. The variability in clinical practice and adherence to guidelines across different populations underscores the need for standardized protocols and further research to optimize care for these vulnerable groups.
Key Recommendations
References
1 Coetzee B, Nel DG, Visser J. Healthcare Professionals' Knowledge, Attitudes and Practices Toward Providing Artificial Nutrition and Hydration for Patients With Terminal Cancer. Journal of human nutrition and dietetics : the official journal of the British Dietetic Association 2025. link 2 Cheng H, Leung CWL, Ng JSC, Wong KH, Natarajan D, Chan LM et al.. Associations of dyadic appraisal of cancer cachexia symptoms with psychological distress and quality of life in dyads of palliative care patients: a longitudinal mixed-methods study protocol. BMC palliative care 2025. link 3 Assumpção PP, Silva JMCD, Calcagno DQ, Barra WF, Ishak G, Kassab P. OLIGOMETASTASIS IN GASTRIC CANCER TREATMENT: IS THERE A PLACE FOR THE SURGEON?. Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery 2023. link 4 Koemans WJ, van der Kaaij RT, Boot H, Buffart T, Veenhof AAFA, Hartemink KJ et al.. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II). BMC cancer 2019. link 5 Nowacki M, Grzanka D, Zegarski W. Pressurized intraperitoneal aerosol chemotheprapy after misdiagnosed gastric cancer: Case report and review of the literature. World journal of gastroenterology 2018. link 6 Terawaki K, Kashiwase Y, Sawada Y, Hashimoto H, Yoshimura M, Ohbuchi K et al.. Development of ghrelin resistance in a cancer cachexia rat model using human gastric cancer-derived 85As2 cells and the palliative effects of the Kampo medicine rikkunshito on the model. PloS one 2017. link 7 Helfenstein SF, Uster A, Rühlin M, Pless M, Ballmer PE, Imoberdorf R. Are Four Simple Questions Able to Predict Weight Loss in Outpatients With Metastatic Cancer? A Prospective Cohort Study Assessing the Simplified Nutritional Appetite Questionnaire. Nutrition and cancer 2016. link 8 Zhang X, Li N, Wei W, Yao W, Xie K, Hu J et al.. Clinical management of gastric cancer: results of a multicentre survey. BMC cancer 2011. link 9 Nevo Y, Morency D, Kammili A, Abdrabo L, Zullo K, Almatar S et al.. The Role of Palliative Surgery in Stage IV Gastric Cancer: A Retrospective Study. Journal of palliative care 2022. link 10 Chan WL, Yuen KK, Siu SW, Lam KO, Kwong DL. Third-line systemic treatment versus best supportive care for advanced/metastatic gastric cancer: A systematic review and meta-analysis. Critical reviews in oncology/hematology 2017. link 11 Liu J, Huang XE. Clinical application of serum tumor abnormal protein from patients with gastric cancer. Asian Pacific journal of cancer prevention : APJCP 2015. link 12 Namal E, Ercetin C, Tokocin M, Akcali Z, Yigitbas H, Yavuz E et al.. Survival effect of supportive care services for Turkish patients with metastatic gastric cancer. Asian Pacific journal of cancer prevention : APJCP 2015. link